S1 Ep18: FDA Approval Insights: Ponatinib in Ph+ ALL

from OncLive® On Air · host OncLive® On Air

Dr Jabbour expands on the multiple milestones achieved through ponatinib’s FDA approval for patients with Ph-positive ALL; the agent’s potency and unique mechanism of action; and key efficacy and safety data from the PhALLCON trial supporting this regulatory decision.

Episode metadata supplied by the publisher feed · Published Apr 8, 2024

Embed this episode

Attribution link and audio player

NOW PLAYING

S1 Ep18: FDA Approval Insights: Ponatinib in Ph+ ALL

0:00 9:19

1×

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

Share this episode

Similar Episodes

No similar episodes found.

Similar Podcasts

No similar podcasts found.

Frequently Asked Questions

How long is this episode of OncLive® On Air?

This episode is 9 minutes long.

When was this OncLive® On Air episode published?

This episode was published on April 8, 2024.

Can I download this OncLive® On Air episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.

URL copied to clipboard!